Overview

A Study of CP-4126 in Patients With Advanced Pancreatic Cancer

Status:
Completed
Trial end date:
2011-09-01
Target enrollment:
Participant gender:
Summary
The main objective of this study is to assess the biological activity of CP-4126 in patients with advanced pancreatic cancer. In addition, the correlation between hENT1 (human equilibrative nucleoside transporter 1) and overall survival will be studied.
Phase:
Phase 2
Details
Lead Sponsor:
Clavis Pharma